CELLINK announces extension of collaboration with AstraZeneca to use CELLINKs? 3D-bioprinting and associated technology for drug discovery
[caption id="attachment_9277" align="alignnone" width="1079"]
CELLINK scientists will continue to work side-by-side in AstraZeneca labs, aiming to speed discovery of new therapies
CELLINK, focused on the commercialization of innovative technologies for bioprinting and associated technologies for preparation and analysis of 3D-bioprinted tissues, announced today that the company has renewed its agreement to collaborate with the global biopharmaceutical company AstraZeneca for an additional 12 months. CELLINK will provide bioprinters and bioinks to accelerate the exploration of new disease targets in AstraZeneca?s main therapeutic areas, including oncology, respiratory, and cardiovascular, renal and metabolic diseases.
The renewal will leverage CELLINK?s growing portfolio of products which are designed to create a seamless workflow from pre-bioprinting preparation of cells through to post-bioprinting analysis. CELLINK will continue to provide a small team of experts to work side-by-side with AstraZeneca scientists at their Gaithersburg, US, R&D strategic center. AstraZeneca will provide expertise in pharmaceutical development to help CELLINK further refine its product offerings to the needs of the industry.
For further information, please contact:
Erik Gatenholm, CEO ??????????????????????????????????????????????????????????????? Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?Phone (US): +1 (857) 332 2138
E-mail:?eg@cellink.com? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ??? ? ? E-mail: gd@cellink.com
About CELLINK
CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the Company?s certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.
?About Us
CELLINK has created one of the world's first universal Bioinks currently used by many of the world's most renowned research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in 3D-Bioprinters. CELLINKs universal Bioink show excellent results and can be used in both CELLINKs proprietary 3D Bioprinters and its? competitors.
?Contacts
Gusten Danielsson
CFO
+46709918604
http://www.cellink.com
gd@cellink.com
Erik Gatenholm
CEO
675 W Kendall St, Cambridge, MA 02142 USA
+1 650 515 5566
http://www.cellink.com
eg@cellink.com[/caption]
CELLINK scientists will continue to work side-by-side in AstraZeneca labs, aiming to speed discovery of new therapiesCELLINK, focused on the commercialization of innovative technologies for bioprinting and associated technologies for preparation and analysis of 3D-bioprinted tissues, announced today that the company has renewed its agreement to collaborate with the global biopharmaceutical company AstraZeneca for an additional 12 months. CELLINK will provide bioprinters and bioinks to accelerate the exploration of new disease targets in AstraZeneca?s main therapeutic areas, including oncology, respiratory, and cardiovascular, renal and metabolic diseases.
The renewal will leverage CELLINK?s growing portfolio of products which are designed to create a seamless workflow from pre-bioprinting preparation of cells through to post-bioprinting analysis. CELLINK will continue to provide a small team of experts to work side-by-side with AstraZeneca scientists at their Gaithersburg, US, R&D strategic center. AstraZeneca will provide expertise in pharmaceutical development to help CELLINK further refine its product offerings to the needs of the industry.
For further information, please contact:
Erik Gatenholm, CEO ??????????????????????????????????????????????????????????????? Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?Phone (US): +1 (857) 332 2138
E-mail:?eg@cellink.com? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ??? ? ? E-mail: gd@cellink.com
About CELLINK
CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the Company?s certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.
?About Us
CELLINK has created one of the world's first universal Bioinks currently used by many of the world's most renowned research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in 3D-Bioprinters. CELLINKs universal Bioink show excellent results and can be used in both CELLINKs proprietary 3D Bioprinters and its? competitors.
?Contacts
Gusten Danielsson
CFO
+46709918604
http://www.cellink.com
gd@cellink.com
Erik Gatenholm
CEO
675 W Kendall St, Cambridge, MA 02142 USA
+1 650 515 5566
http://www.cellink.com
eg@cellink.com[/caption]
